NCT02363101

Brief Summary

The purpose of this study is to evaluate the costs, health-related quality of life and preference values from lung cancer patients assisted in a Brazilian public health care unit.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
300

participants targeted

Target at P75+ for all trials

Timeline
Completed

Started Mar 2015

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

February 9, 2015

Completed
4 days until next milestone

First Posted

Study publicly available on registry

February 13, 2015

Completed
16 days until next milestone

Study Start

First participant enrolled

March 1, 2015

Completed
1 year until next milestone

Primary Completion

Last participant's last visit for primary outcome

March 1, 2016

Completed
9 months until next milestone

Study Completion

Last participant's last visit for all outcomes

December 1, 2016

Completed
Last Updated

March 4, 2015

Status Verified

March 1, 2015

Enrollment Period

1 year

First QC Date

February 9, 2015

Last Update Submit

March 3, 2015

Conditions

Lung Cancer

Outcome Measures

Primary Outcomes (3)

  • Direct costs

    Direct costs related to each procedure involved on lung cancer

    one year

  • HRQoL

    up to 30 days after the procedure

  • Preference values

    Evaluate preference values in hypothetic scenarios

    cross sectional

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

Lung cancer patients from Instituto Nacional de Câncer during one year.

You may qualify if:

  • Clinical diagnosis of lung cancer disease
  • Able to understand the overall concept of study and sign the written informed consent

You may not qualify if:

  • Illiterate
  • Visible cognitive impaired
  • Non-primary lung tumor

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

INCA - Instituto Nacional de Câncer

Rio de Janeiro, Rio de Janeiro, Brazil

Location

MeSH Terms

Conditions

Lung Neoplasms

Condition Hierarchy (Ancestors)

Respiratory Tract NeoplasmsThoracic NeoplasmsNeoplasms by SiteNeoplasmsLung DiseasesRespiratory Tract Diseases

Study Officials

  • Carlos Gil Ferreira

    National Cancer Institute, France

    PRINCIPAL INVESTIGATOR

  • Luciene Schluckebier

    National Cancer Institute, France

    STUDY DIRECTOR

  • Marisa Santos

    INC

    STUDY CHAIR

  • Bruna Carvalho

    National Cancer Institute, France

    STUDY CHAIR

  • Pedro Masson

    National Cancer Institute, France

    STUDY CHAIR

  • Andréa Monteiro

    INC

    STUDY CHAIR

  • Bruna Medeiros

    INC

    STUDY CHAIR

  • Kátia Senna

    INC

    STUDY CHAIR

  • Márcia Gisele

    INC

    STUDY CHAIR

Central Study Contacts

Luciene Schluckebier

CONTACT

552132076660lschluckebier@inca.gov.br

Alessandra Marins

CONTACT

55 21 32076569amarins@inca.gov.br

Study Design

Study Type
observational
Time Perspective
CROSS SECTIONAL
Sponsor Type
OTHER GOV
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
MD PHD

Study Record Dates

First Submitted

February 9, 2015

First Posted

February 13, 2015

Study Start

March 1, 2015

Primary Completion

March 1, 2016

Study Completion

December 1, 2016

Last Updated

March 4, 2015

Record last verified: 2015-03

Locations

BR(1)